Cytos Biotechnology Ag

Michigan State University

Kuros Biosciences Ag

Saiba Ag

Saiba Gmbh

Kuros US LLC

Paul Pumpens

Martin F Bachmann

Alain Tissot

Indulis Cielens

Regina Renhofa

Patrik Maurer

Martin Bachmann

Edwin Meijerink

Katrin Schwarz

Andris Zeltins

Tazio Storni

Gerd Lipowsky

Wolfgang Andreas Renner

Vania Manolova

James J Ireland

Sebastian Fuchs

Conrad Coester

Klaus Dietmeier

Yu Zou

Dace Skrastina

Galina Borisova

Guna Mezule

Patrick Maurer

Gerad Lipowsky

The present invention relates to virus-like particles of plant virus Cucumber Mosaic Virus (CMV), and in particular to modified VLPs of CMV comprising Th cell epitopes, in particular universal Th cell epitopes. Furthermore, these modified VLPs serve as, preferably, vaccine platform, for generating immune responses, in particular antibody responses, against antigens linked to said modified VLPs. The presence of the Th cell epitopes, in particular universal Th cell epitopes, led to a further increase in the generated immune response.

Modified virus-like particles of CMV

The invention relates to the finding that virus like particles (VLPs) can be loaded with immunostimulatory substances, in particular with DNA oligonucleotides containing non-methylated C and G (CpGs). Such CpG-VLPs are dramatically more immunogenic than their CpG-free counterparts and induce enhanced B and T cell responses. The immune response against antigens optionally coupled, fused or attached otherwise to the VLPs is similarly enhanced as the immune response against the VLP itself. In addition, the T cell responses against both the VLPs and antigens are especially directed to the Th1 type. Antigens attached to CpG-loaded VLPs may therefore be ideal vaccines for prophylactic or therapeutic vaccination against allergies, tumors and other self-molecules and chronic viral diseases.

Packaging of immunostimulatory substances into virus-like particles: method of preparation and use

The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.

Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.

Molecular antigen arrays

A fusion protein formed of an antigenic inhibin peptide inserted into hepatitis B capsid protein is expressed from a chimeric gene forming an effective immunogen which induces anti-inhibin antibodies when administered to a host animal.

Inhibin-HBc fusion protein

Growing community of inventors

Riga, Latvia

Paul Pumpens